Lew A S, Laramee P, Cercek B, Rodriguez L, Ganz W
Z Kardiol. 1985;74 Suppl 6:129-34.
This report compares the results of intracoronary (IC) and intravenous (IV) streptokinase in a sequential series of 200 patients (IC = 81 and IV = 119) admitted within 3 hours of the onset of an acute myocardial infarction. Reperfusion was achieved in 71 of 81 (88%) patients in the IC group and in 113 of 119 (95%) patients in the IV group (p = NS) 35 +/- 27 and 42 +/- 33 minutes after commencement of treatment respectively (p = NS). The interval from onset of symptoms to reperfusion was significantly longer in the IC than in the IV group, 235 +/- 62 versus 175 +/- 61 minutes (p less than 0.001). Mean values of peak creatine kinase-MB were 152 +/- 117 IU/L in the IC group and 117 +/- 79 IU/L in the IV group (p less than 0.05). Three patients in the IC group and 16 patients in the IV group suffered major hemorrhagic complications. In-hospital mortality was 7 of 81 (8.7%) in the IC group and 10 of 119 (8.4%) in the IV group (p = NS). We conclude that IV administration of streptokinase in patients with an acute myocardial infarction is at least as efficacious as IC administration.
本报告比较了200例在急性心肌梗死发作3小时内入院的患者(冠状动脉内给药组81例,静脉给药组119例)接受冠状动脉内(IC)和静脉内(IV)链激酶治疗的结果。IC组81例患者中有71例(88%)实现再灌注,IV组119例患者中有113例(95%)实现再灌注(p=无显著性差异),分别在治疗开始后35±27分钟和42±33分钟实现再灌注(p=无显著性差异)。IC组从症状发作到再灌注的时间显著长于IV组,分别为235±62分钟和175±61分钟(p<0.001)。IC组肌酸激酶同工酶峰值的平均值为152±117 IU/L,IV组为117±79 IU/L(p<0.05)。IC组有3例患者和IV组有16例患者发生严重出血并发症。IC组81例患者中有7例(8.7%)院内死亡,IV组119例患者中有10例(8.4%)院内死亡(p=无显著性差异)。我们得出结论,急性心肌梗死患者静脉注射链激酶至少与冠状动脉内注射一样有效。